A new study of cervical cancer patients has revealed that irrespective of being big or small, if a tumour glows brightly in a PET (positron emission tomography) scan, it is likely to be more dangerous than dimmer tumours.
The study conducted by Washington University School of Medicine researchers reveals that PET ‘can reliably identify patients who have a poorer prognosis’.
"We've seen that among patients with the same stage of cervical cancer, there will be some patients who don't respond to treatment as well as others," said lead author Elizabeth A. Kidd, M.D., a Barnes-Jewish Hospital resident in Washington University's Department of Radiation Oncology.
"Our study suggests that PET (positron emission tomography) can reliably identify patients who have a poorer prognosis." A. Kidd added.
The researchers used FDG-PET, a widely available three-dimensional scanning technique. FDG-PET measures how rapidly tumours take up a radio labelled glucose tracer.
(FDG) — high uptake results in a stronger or brighter signal in the scan. The researchers found that the higher the standard uptake value (SUV) for FDG in the primary tumour, the greater the recurrence rate and the lower the survival rate of patients.
"FDG-PET is the most commonly used PET scan. It's standard for patients to have this type of scan once diagnosed with cervical cancer. Oncologists use it to see the extent of the primary tumour and to look for tumours that have spread beyond the pelvis. But this study shows that the SUV obtained from FDG-PET can also tell physicians how well a patient will respond to treatment and should be part of the evaluation process," Kidd explained.